You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 65 No. 6, June 2008 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (55)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Neurology, Other
 •Transplantation
 •Bone Marrow Transplantation
 •Transplantation, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Neuroprotection and Immunomodulation With Mesenchymal Stem Cells in Chronic Experimental Autoimmune Encephalomyelitis

Ibrahim Kassis, MSc; Nikolaos Grigoriadis, MD, PhD; Basan Gowda-Kurkalli, PhD; Rachel Mizrachi-Kol, MsC{dagger}; Tamir Ben-Hur, MD, PhD; Shimon Slavin, MD; Oded Abramsky, MD, PhD; Dimitrios Karussis, MD, PhD

Arch Neurol. 2008;65(6):753-761.

Objective  To investigate the therapeutic potential of mesenchymal stromal cells (MSCs) in the chronic model of experimental autoimmune encephalomyelitis (EAE).

Design  Mesenchymal stromal cells were obtained from the bone marrow of naïve C57BL and green fluorescent protein–transgenic mice and cultured with Eagle minimum essential medium/alpha medium after removal of adhering cells. Following 2 to 3 passages, MSCs were injected intraventricularly or intravenously into mice in which chronic EAE had been induced with myelin oligodendrocyte glycoprotein 35-55 peptide.

Results  In 8 separate experiments, the intravenously and intraventricularly injected green fluorescent protein–positive MSCs were attracted to the areas of central nervous system inflammation and expressed galactocerebroside, O4, glial fibrillary acidic protein, and β-tubulin type III. The clinical course of chronic EAE was ameliorated in MSC-treated animals (0% mortality; mean [SE] maximal EAE score, 1.76 [1.01] and 1.8 [0.46] in the intraventricular and intravenous groups, respectively, vs 13% and 21% mortality and 2.80 [0.79] and 3.42 [0.54] mean maximal score in the controls). A strong reduction in central nervous system inflammation, accompanied by significant protection of the axons (86%-95% intact axons vs 45% in the controls) was observed in the animals injected with MSCs (especially following intraventricular administration). Mesenchymal stromal cells injected intravenously were detected in the lymph nodes and exhibited systemic immunomodulatory effects, downregulating proliferation of lymphocytes in response to myelin antigens and mitogens. Mesenchymal stromal cells cultured with fibroblast growth factor and brain-derived neurotrophic factor in vitro acquired neuronal-lineage cell morphology and expressed β-tubulin type III, nestin glial fibrillary acidic protein, and O4.

Conclusions  Our results indicate that stem cells derived from bone marrow may provide a feasible and practical way for neuroprotection, immunomodulation, and possibly remyelination and neuroregeneration in diseases such as multiple sclerosis.



Author Affiliations: Department of Neurology and the Agnes-Ginges Center for Neurogenetics (Mr Kassis, Ms Mizrachi-Kol, and Drs Ben-Hur, Abramsky, and Karussis) and Department of Bone Marrow Transplantation (Drs Gowda-Kurkalli and Slavin), Hadassah-Hebrew University Hospital, Jerusalem, Israel; and Department of Neurology, AHEPA Hospital, Aristotle University, Thessaloniki, Greece (Dr Grigoriadis).
{dagger}Deceased.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

How Safe Could Intrathecal Transplantation of Mesenchymal Stem Cells Be Considered in Multiple Sclerosis?
Dimitris Karacostas, George Hadjigeorgiou, Panos Ioannidis, and Ioannis Milonas
Arch Neurol. 2011;68(7):955.
EXTRACT | FULL TEXT  

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(6):695-697.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How Safe Could Intrathecal Transplantation of Mesenchymal Stem Cells Be Considered in Multiple Sclerosis?
Karacostas et al.
Arch Neurol 2011;68:955-955.
FULL TEXT  

Intravitreal Injections of Neurotrophic Factors Secreting Mesenchymal Stem Cells Are Neuroprotective in Rat Eyes following Optic Nerve Transection
Levkovitch-Verbin et al.
IOVS 2010;51:6394-6400.
ABSTRACT | FULL TEXT  

Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis
Karussis et al.
Arch Neurol 2010;67:1187-1194.
ABSTRACT | FULL TEXT  

Neuroprotective Effects of Intravitreal Mesenchymal Stem Cell Transplantation in Experimental Glaucoma
Johnson et al.
IOVS 2010;51:2051-2059.
ABSTRACT | FULL TEXT  

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Freedman et al.
Mult Scler 2010;16:503-510.
ABSTRACT  

Transplanted Oligodendrocyte Precursor Cells Reduce Neurodegeneration in a Model of Glaucoma
Bull et al.
IOVS 2009;50:4244-4253.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.